Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients

Nicole Zatorski; Eric A Sobie; Avner Schlessinger

doi:10.1016/j.tips.2023.02.005

Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients

Trends Pharmacol Sci. 2023 May;44(5):318-319. doi: 10.1016/j.tips.2023.02.005. Epub 2023 Mar 12.

Authors

Nicole Zatorski¹, Eric A Sobie², Avner Schlessinger³

Affiliations

¹ Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: nicole.zatorski@icahn.mssm.edu.
² Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
³ Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: avner.schlessinger@mssm.edu.

Abstract

STRUCTURE: Mavacamten, 3-(1-methylethyl)-6-[[(1S)-1-phenylethyl]amino]-2,4(1H,3H)-pyrimidinedione, is a reversible small-molecule allosteric inhibitor of cardiac myosin ATPase with a molecular formula of C₁₅H₁₉N₃O₂ and molecular weight of 273.33 g/mol. It belongs to the pyrimidinedione drug class.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Benzylamines
Cardiomyopathy, Hypertrophic* / drug therapy
Humans
Uracil

Substances

MYK-461
Benzylamines
Uracil

Grants and funding

F30 HL160179/HL/NHLBI NIH HHS/United States